Related Experiment Video
Updated: Jun 19, 2026

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
Published on: August 8, 2022
Etiopathogenesis of cardiomyopathies: a review
I Kirvalidze1, T Jorbenadze, R Khetsuriani
1Tbilisi Scientific Practical Center of Clinical Pathology.
Insights
Cardiomyopathy remains a complex heart condition with unclear causes and treatments. Further research is needed to understand factors affecting heart function and develop new therapies.
Area of Science:
- Cardiology
- Pathology
- Virology
Background:
- Cardiomyopathy etiology, pathogenesis, and classification lack universal consensus.
- Coxsackie B viruses and smoking are implicated in cardiomyopathy development.
- Distinguishing congestive and ischemic cardiomyopathy presents diagnostic challenges.
Purpose of the Study:
- To review the etiopathogenesis of cardiomyopathy.
- To highlight the need for further investigation into unexplored aspects of cardiomyopathy.
- To identify factors influencing cardiac contractile function.
Main Methods:
- Literature review of etiopathogenesis of cardiomyopathy.
- Analysis of etiological factors including viral infections and environmental influences like smoking.
- Discussion of diagnostic complexities and current terminology.
Main Results:
- Etiology and pathogenesis of cardiomyopathy are not fully understood.
- Smoking significantly impacts cellular oxidative and energetic processes, relevant to cardiomyopathy.
- Clinical presentation of congestive and ischemic cardiomyopathy can be similar, necessitating careful diagnosis.
Conclusions:
- Cardiomyopathy is a complex pathology requiring further etiological and pathogenetic investigation.
- Understanding factors affecting cardiac contractile function is crucial.
- Development of novel therapeutic agents is essential for effective cardiomyopathy management.
Abstract:
An article reviews etiopathogenesis of cardiomyopathy. Regardless of the fact that many early days' fundamental investigations are devoted to cardiomyopathy problem, still there is no common consideration concerning the etiology, pathogenesis, morphogenesis, classification and therapy of cardiomyopathy as well. Problem concerning the etiology of cardiomyopathy appear of particular interest. Great number of authors put an emphasis on the role of coxsackie B viruses' group encompasses enteroviruses with well defined cardiotropic features. Smoking is believed to play significant role in the evolution of cardiomyopathy, having drastic effect on the oxidative and energetic processes of the cells. Consequently, the phrase "cardiomyopathy during smoking" seems quite relevant. On behalf of World Public Health Services recommendation the term cardiomyopathy encloses patients with myocarditis of unknown origin with well defined characteristic features - megalocardia and cardiac decompensation. However, heart valve, coronary and lung vessels injuries are excluded. Note worthily, concept "secondary cardiomyopathy" is not well interpreted, especially as in this case etiology is well understood. Due to the complexity of differential diagnostics for congestive cardiomyopathy and myocardial ischemia in present day literature the term "ischemic cardiomyopathy" is widely applicable. Frequently, patients with congestive cardiomyopathy and myocardial ischemia reveal identical clinical-angiocardiographic set of symptoms determined by generalized injury of cardiac muscle. Taking into account all the above mentioned data it is evident that regarding etio pathogenesis and morphogenesis cardiomyopathy is not completely explored pathology and needs further investigation. The goal here is revelation of factors affecting cardiac contractile function. Besides, elaboration of new, effective pharmaceutical means seems of great importance.
Related Concept Videos
Cardiomyopathy I: Introduction and Classification
Myocarditis I: Introduction
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Cardiomyopathy II: Dilated Cardiomyopathy
Cardiomyopathy V: Interprofessional Care
Cardiomyopathy IV: Restrictive Cardiomyopathy

